Zobrazeno 1 - 10
of 92
pro vyhledávání: '"YASUSHI IDE"'
Autor:
Taro Shibuki, Taiga Otsuka, Mototsugu Shimokawa, Junichi Nakazawa, Shiho Arima, Masaru Fukahori, Keisuke Miwa, Yoshinobu Okabe, Futa Koga, Yujiro Ueda, Yoshihito Kubotsu, Akitaka Makiyama, Hozumi Shimokawa, Shigeyuki Takeshita, Kazuo Nishikawa, Azusa Komori, Satoshi Otsu, Ayumu Hosokawa, Tatsunori Sakai, Hisanobu Oda, Machiko Kawahira, Shuji Arita, Takuya Honda, Hiroki Taguchi, Kengo Tsuneyoshi, Yasunori Kawaguchi, Toshihiro Fujita, Takahiro Sakae, Kenta Nio, Yasushi Ide, Norio Ureshino, Tsuyoshi Shirakawa, Toshihiko Mizuta, Kenji Mitsugi
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-10 (2024)
Abstract This study aimed to compare second-line treatment outcomes for patients with unresectable pancreatic cancer previously treated with gemcitabine plus nab–paclitaxel (GnP) therapy. We conducted an integrated analysis of two retrospective stu
Externí odkaz:
https://doaj.org/article/e7f02c7dbce94342bdbac0633ca1ffca
Autor:
Masaru Fukahori, Yoshinobu Okabe, Mototsugu Shimokawa, Taiga Otsuka, Futa Koga, Yujiro Ueda, Junichi Nakazawa, Azusa Komori, Satoshi Otsu, Shiho Arima, Akitaka Makiyama, Hiroki Taguchi, Takuya Honda, Tomoyuki Ushijima, Keisuke Miwa, Taro Shibuki, Kenta Nio, Yasushi Ide, Norio Ureshino, Toshihiko Mizuta, Kenji Mitsugi, Tsuyoshi Shirakawa
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-10 (2023)
Abstract First-line chemotherapy for patients with metastatic pancreatic cancer (MPC) includes gemcitabine plus nab-paclitaxel (GnP) and FOLFIRINOX (FFX). However, the efficacy of second-line chemotherapy and the role of combination chemotherapy in c
Externí odkaz:
https://doaj.org/article/f5f37084f80443099bd5a4c15daea257
Autor:
Tsuyoshi Shirakawa, Akitaka Makiyama, Mototsugu Shimokawa, Taiga Otsuka, Yudai Shinohara, Futa Koga, Yujiro Ueda, Junichi Nakazawa, Satoshi Otsu, Azusa Komori, Shiho Arima, Masaru Fukahori, Hiroki Taguchi, Takuya Honda, Taro Shibuki, Kenta Nio, Yasushi Ide, Norio Ureshino, Toshihiko Mizuta, Kenji Mitsugi, Koichi Akashi, Eishi Baba
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-12 (2023)
Abstract There are limited absolute biomarkers for determining the prognosis before first- and second-line palliative chemotherapy in unresectable pancreatic cancer (urPC) patients. To find the best prognostic inflammatory marker, we investigated rel
Externí odkaz:
https://doaj.org/article/bc6dd35d26fe4df2aa0b662a99f00fd2
Autor:
Tsuyoshi Shirakawa, Akitaka Makiyama, Mototsugu Shimokawa, Taiga Otsuka, Yudai Shinohara, Futa Koga, Yujiro Ueda, Junichi Nakazawa, Satoshi Otsu, Azusa Komori, Shiho Arima, Masaru Fukahori, Hiroki Taguchi, Takuya Honda, Taro Shibuki, Kenta Nio, Yasushi Ide, Norio Ureshino, Toshihiko Mizuta, Kenji Mitsugi, Koichi Akashi, Eishi Baba
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-1 (2024)
Externí odkaz:
https://doaj.org/article/10e1b3b0ad7e4fab943321b093b93e3e
Autor:
Taro Shibuki, Toshihiko Mizuta, Mototsugu Shimokawa, Futa Koga, Yujiro Ueda, Junichi Nakazawa, Azusa Komori, Satoshi Otsu, Shiho Arima, Masaru Fukahori, Akitaka Makiyama, Hiroki Taguchi, Takuya Honda, Kenji Mitsugi, Kenta Nio, Yasushi Ide, Norio Ureshino, Tsuyoshi Shirakawa, Taiga Otsuka
Publikováno v:
BMC Cancer, Vol 22, Iss 1, Pp 1-11 (2022)
Abstract Background No reliable nomogram has been developed until date for predicting the survival in patients with unresectable pancreatic cancer undergoing treatment with gemcitabine plus nab–paclitaxel (GnP) or FOLFIRINOX. Methods This analysis
Externí odkaz:
https://doaj.org/article/eb35e2af95fa4d798ff5388601ac6ee0
Autor:
Toshie Mashiba, Kouji Joko, Masayuki Kurosaki, Hironori Ochi, Yukio Osaki, Yuji Kojima, Ryo Nakata, Tohru Goto, Akahane Takehiro, Hiroyuki Kimura, Akeri Mitsuda, Chiharu Kawanami, Yasushi Uchida, Chikara Ogawa, Atsunori Kusakabe, Ryuichi Narita, Yasushi Ide, Takehiko Abe, Keiji Tsuji, Tadashi Kitamura, Kazuhiko Okada, Tetsuro Sohda, Masaya Shigeno, Takashi Satou, Namiki Izumi
Publikováno v:
PLoS ONE, Vol 13, Iss 4, p e0194704 (2018)
This study aimed to elucidate whether interferon (IFN)-free direct-acting antiviral (DAA) therapy for hepatitis C after curative treatment of hepatocellular carcinoma (HCC) promotes HCC recurrence in a real-world large-scale cohort.This multicenter s
Externí odkaz:
https://doaj.org/article/fa8946d099b443f1b37b8da73dbc579e
Autor:
Jun Itakura, Masayuki Kurosaki, Chitomi Hasebe, Yukio Osaki, Kouji Joko, Hitoshi Yagisawa, Shinya Sakita, Hiroaki Okushin, Takashi Satou, Hiroyuki Hisai, Takehiko Abe, Keiji Tsuji, Takashi Tamada, Haruhiko Kobashi, Akeri Mitsuda, Yasushi Ide, Chikara Ogawa, Syotaro Tsuruta, Kouichi Takaguchi, Miyako Murakawa, Yasuhiro Asahina, Nobuyuki Enomoto, Namiki Izumi
Publikováno v:
PLoS ONE, Vol 11, Iss 10, p e0165339 (2016)
We aimed to clarify the characteristics of resistance-associated substitutions (RASs) after treatment failure with NS5A inhibitor, daclatasvir (DCV) in combination with NS3/4A inhibitor, asunaprevir (ASV), in patients with chronic hepatitis C virus g
Externí odkaz:
https://doaj.org/article/b9240e38227148be9226cb4333c32437
Autor:
YASUSHI IDE, TAIGA OTSUKA, MOTOTSUGU SHIMOKAWA, FUTA KOGA, YUJIRO UEDA, JUNICHI NAKAZAWA, AZUSA KOMORI, SATOSHI OTSU, SHIHO ARIMA, MASARU FUKAHORI, AKITAKA MAKIYAMA, YUDAI SHINOHARA, SHOHEI UENO, HIROKI TAGUCHI, TAKUYA HONDA, TARO SHIBUKI, KENTA NIO, NORIO URESHINO, TOSHIHIKO MIZUTA, KENJI MITSUGI, TSUYOSHI SHIRAKAWA
Publikováno v:
Anticancer Research. 43:1817-1826
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::22800627150461a7173ef79735b8dec4
https://doi.org/10.21873/anticanres.16335
https://doi.org/10.21873/anticanres.16335
Autor:
Azusa Komori, Satoshi Otsu, Mototsugu Shimokawa, Taiga Otsuka, Futa Koga, Yujiro Ueda, Junichi Nakazawa, Shiho Arima, Masaru Fukahori, Yoshinobu Okabe, Akitaka Makiyama, Hiroki Taguchi, Takuya Honda, Taro Shibuki, Kenta Nio, Yasushi Ide, Norio Ureshino, Toshihiko Mizuta, Tsuyoshi Shirakawa, Kenji Mitsugi
Publikováno v:
International Journal of Clinical Oncology.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e708dc50636a9ac6c197ff6c1874ee0f
https://doi.org/10.1007/s10147-023-02354-6
https://doi.org/10.1007/s10147-023-02354-6
Autor:
Takashi Sato, Hiroyuki Kimura, Chikara Ogawa, Hirotaka Arai, Nami Mori, Masayuki Kurosaki, Atsunori Kusakabe, Takehiro Akahane, Kouji Joko, Masahiko Kondo, Chitomi Hasebe, Yasushi Ide, Shinichiro Nakamura, Koichiro Furuta, Toshifumi Tada, Akeri Mitsuda, Namiki Izumi, Hitoshi Yagisawa, Yasushi Uchida, Hiroyuki Marusawa, Haruhiko Kobashi, Yuji Kojima, Ryoichi Narita, Keiji Tsuji
Publikováno v:
Journal of Medical Virology. 93:6247-6256
The real-world virological efficacy and safety of interferon-free direct-acting antiviral (DAA) therapy with sofosbuvir (SOF) and velpatasvir (VEL) were assessed in hepatitis C virus (HCV) genotype 1- and 2-infected patients with decompensated cirrho
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f2a82460d15c40a60aa82a873555a688
https://doi.org/10.1002/jmv.27157
https://doi.org/10.1002/jmv.27157